Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of Neoadjuvant Chemoradiation Plus PD-1 Antibody(SHR-1210) in the Locally Advanced Proximal Stomach Adenocarcinoma (Neo-PLANET)

Next Previous
Trial Profile

A Phase II Study of Neoadjuvant Chemoradiation Plus PD-1 Antibody(SHR-1210) in the Locally Advanced Proximal Stomach Adenocarcinoma (Neo-PLANET)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camrelizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin (Primary)
  • Indications Adenocarcinoma; Gastric cancer
  • Focus Therapeutic Use
  • Acronyms Neo-PLANET

    • Most Recent Events

    • 21 Sep 2021 Results assessing the efficacy and safety of camrelizumab plus chemoradiation as neoadjuvant therapy for locally advanced proximal gastric cancer, presented at the 46th European Society for Medical Oncology Congress.
    • 21 Sep 2020 Interim results (N=15), presented at the 45th European Society for Medical Oncology Congress
    • 24 Aug 2020 Planned End Date changed from 1 Oct 2020 to 1 Dec 2020.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top